Effect of telavancin (vibativ) on routine coagulation test results

American Journal of Clinical Pathology

Volumn 136, Issue 6, 2011, Pages 848-854

  Gosselin, Robert ^a   Dager, William ^a   Roberts, Aaron ^a   Freeman, Leslie ^a   Gandy, Lisa ^a   Gregg, Jeffrey ^a   Dwyre, Denis ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Activated partial thromboplastin time; aPTT; Coagulation tests; INR; International normalized ratio; Telavancin

Indexed keywords

D DIMER; FIBRINOGEN; PROTEIN C; PROTEIN S; RECOMBINANT THROMBOPLASTIN; TELAVANCIN;

ARTICLE; BLOOD CLOTTING TEST; BLOOD CLOTTING TIME; CONCENTRATION RESPONSE; FALSE POSITIVE RESULT; HUMAN; INTERNATIONAL NORMALIZED RATIO; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; THROMBIN TIME;

AMINOGLYCOSIDES; BLOOD COAGULATION; BLOOD COAGULATION TESTS; DRUG ADMINISTRATION SCHEDULE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FIBRINOGEN; HUMANS; INTERNATIONAL NORMALIZED RATIO; PARTIAL THROMBOPLASTIN TIME; PROTHROMBIN TIME; RECOMBINANT PROTEINS; THROMBIN TIME; THROMBOPLASTIN;

EID: 82655181346     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCPDPL4G7CERYJU     Document Type: Article

References (10)

1. Chang MH, Kish TD, Fung HB. Telavancin: a lipoglycopeptide antimicrobial for the treatment of complicated skin and skin structure infections caused by gram positive bacteria in adults. Clin Ther. 2010;32:2160-2185.
2. Stryjewski ME, Chu VH, O'Riorda WD, et al. Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study. Antimicrob Agents Chemother. 2006;50:862-867. (Pubitemid 43327787)
3. Vibativ [package insert]. Deerfield, IL: Astellas Pharma US; 2009.
4. 14C] telavancin following intravenous administration to healthy male volunteers. Antimicrob Agents Chemother. 2010;54:3365-3371.
5. Wong SL, Barriere SL, Kitt MM, et al. Multiple dose pharmacokinetics of intravenous telavancin in healthy male and female subjects. J Antimicrob Chemother. 2008;62:780-783.
6. Shaw JP, Seroogy J, Kaniga K, et al. Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects. Antimicrob Agents Chemother. 2005;49:195-201. (Pubitemid 40065793)
7. Stryjewski ME, Graham DR, Wilson SE, et al.; for the Assessment of Telavancin in Complicated Skin and Skin-Structure Infections Study. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms. Clin Infect Dis. 2008;46:1683-1693. (Pubitemid 351706765)
8. Bader R, Mannucci PM, Tripodi A, et al. Multicentric evaluation of a new PT reagent based on recombinant human tissue factor and synthetic phospholipids. Thromb Haemost. 1994;71:292-299. (Pubitemid 24083738)
9. Smith SA, Morrissey JH. Properties of recombinant human thromboplastin that determine the International Sensitivity Index (ISI). J Thromb Haemost. 2004;2:1610-1616. (Pubitemid 40186178)
10. Smith SA, Comp PC, Morrissey JH. Phospholipid composition controls thromboplastin sensitivity to individual clotting factors. J Thromb Haemost. 2006;4:820-827.